Diala Alatassi MD

12/01/2025

Study finds orforglipron taken orally once daily leads to significant body weight loss.

New research presented at the Annual Meeting of the European Association for the Study of Diabetes in Vienna, Austria (Sept 15–19) and simultaneously published in NEJM shows that daily treatment with the new once-daily GLP-1 agonist orforglipron results in substantial weight loss in people living ...

11/27/2025

Wishing you and your family a wonderful Thanksgiving!

11/25/2025

Watch, follow, and discover more trending content.

11/24/2025

Weight-loss surgery could help boost work productivity.

A new international QUT-led study found that bariatric surgery improves work productivity and employment rates in the short term—but these gains may not last beyond five years without targeted support.

11/21/2025

Bariatric surgery for weight loss shows greater long-term benefits than GLP-1 medicines.

A large Cleveland Clinic study has found that people with obesity and type 2 diabetes who undergo weight-loss surgery live longer and face fewer serious health problems compared with those treated with GLP-1 receptor agonist medicines alone.

11/11/2025

We thank you for your commitment and celebrate your service.

11/10/2025

Weight loss treatments for people with diabetes and obesity could lower the risk of obesity-related cancers.

Weight loss treatments, including medication and surgical procedures, may help lower the risk of obesity-related cancers in people with obesity and type 2 diabetes, a new study shows.

11/03/2025

Study suggests new drug for weight loss may cause fewer side effects.

A new Penn Nursing study suggests that the weight-loss drug tirzepatide may cause fewer side effects like nausea and vomiting than the drug semaglutide. This research, published in Science Advances, was conducted using preclinical models to study the effects of the drugs.

10/27/2025

Pill form of semaglutide may be a suitable option for adults with overweight or obesity, trial suggests.

A Novo Nordisk designed trial reports that their 25 mg oral semaglutide taken once daily produced greater mean weight reduction than placebo over 64 weeks in adults with overweight or obesity.

09/26/2025

The $15 Supplement Doctors Are Calling ‘Nature’s Ozempic’ for Menopause Weight.

Doctors explain if Berberine, dubbed “Nature’s Ozempic,” can really help with menopause weight loss. Here’s what to know.

09/22/2025

Ecnoglutide yields superior, sustained reduction in body weight: Study.

For adults with obesity or overweight without diabetes, the novel cyclic adenosine monophosphate-biased glucagon-like peptide 1 receptor agonist known as ecnoglutide yields a superior and sustained reduction in body weight versus placebo

09/19/2025

Dr. Diala Alatassi Featured on HealthCentral: Insights on Insulin Resistance.

Signs and symptoms of insulin resistance can include a large waist, other signs of metabolic syndrome, or dark skin patches.